Insmed's (INSM) Brenso Negative Phase 2 Readout A Setback - Cantor Fitzgerald

December 18, 2025 6:58 AM EST Send to a Friend
Cantor Fitzgerald analyst Olivia Brayer reiterated an Overweight rating and $230.00 price target on Insmed (NASDAQ: INSM).The analyst commented, "Not ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login